MorphoSys and Galapagos’ Eczema Drug Abandoned at Phase II

Development of MorphoSys, Galapagos, and Novartis’ first-in-class antibody drug has been discontinued during a phase II trial after an interim analysis suggested it wouldn’t meet its main endpoint of reducing eczema symptoms. The drug was being developed to treat the inflammatory skin condition atopic dermatitis, also known as eczema. It arose from a collaboration between … Continue reading MorphoSys and Galapagos’ Eczema Drug Abandoned at Phase II